Previous Biologic Disease-Modifying Antirheumatic Drug (bDMARD) Exposure and Efficacy and Safety Analysis from a Phase 3 Study of Baricitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to Tumor Necrosis Factor Inhibitors Genovese, M. C., Kremer, J. M., Kartman, C., Schlichting, D. E., Xie, L., Carmack, T., Macias, W. L., Smolen, J. S. WILEY-BLACKWELL. 2015

View details for Web of Science ID 000370860202310